2021 IPO

Humacyte Stock

Regenerative Medical Technology Company

Sign up today and learn more about Humacyte Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

California Institute for Regenerative Medicine


Morrisville NC, US

Total Funding


About Humacyte Stock

Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.


Bangkok bank

Humacyte, R3

California Institute for Regenerative Medicine


Pacific Eagle Asset Management


Funding History

January 2015$74.1M
October 2015$136M
March 2018$75.0M
June 2018$150M


Chief Executive Officer

Jeffrey Lawson

Chief Financial Officer

Douglas Blankenship


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: